Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB063 in Healthy Volunteers
NCT02555085Phase 1Terminated
- Sponsor
- Biogen
- Start
- Sep 2015
- Primary completion
- Jun 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BIIB063 in Sjogren's syndrome (8 arms), sponsored by Biogen. Primary endpoints: Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of participants with clinically significant laboratory assessment abnormalities and 6 more. Started Sep 2015; status: terminated.
02
Drugs
BIIB063
03
Conditions
Sjogren's syndrome
Beyond the preview
Go deeper on NCT02555085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555085.